Tetanus Diphtheria Vaccine
Phase 2Vaccine
Tetanus Diphtheria Vaccine is one of 14 biologic programs targeting High Grade Glioma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in High Grade Glioma
#DrugCompanyPhaseTrials
1Opdualag
Bristol-Myers SquibbPhase 2
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Ojemda
Day One BiopharmaceuticalsPhase 2
Ziagen
GSKPhase 1
Norvir
AbbViePhase 1
Lorbrena
PfizerPhase 1
Mepron
GGlaxo Dba Glaxosmithkline
Phase 1
Epivir
GGlaxo Dba Glaxosmithkline
Phase 1
PEP-CMV
UUniversity of Florida
Phase 2
Lutathera
AAdvanced Accelerator Applications
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tetanus Diphtheria Vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 2[1]
- Company
- NNationwide Children's Hospital